title: Effects of folk medicinal plant extract Ankaferd Blood Stopper(®) in vital primary molar pulpotomy.
abstract: OBJECTIVE
  To compare the clinical and radiographic success rates of two vital pulpotomy agents: formocresol (FC) and Ankaferd Blood Stopper(®) (ABS), in primary molars during a 12-month follow-up period.
  
  
  METHODS
  A randomised, single-blind study design was used in a sample of 30 healthy 6-9 year old children with 60 carious primary molars without clinical or radiographic evidence of pulp degeneration.
  
  
  METHODS
  The pulpotomy agents were assigned as follows: Group 1 was 1:5 diluted Buckley's formocresol (FC) and Group 2 was ABS. Clinical and radiographic follow-up at 3, 6, and 12 months used the following criteria: pain, swelling, sinus tract, mobility, internal root resorption, and furcation and/or periapical bone destruction.
  
  
  METHODS
  The data were analysed using Chi-square tests.
  
  
  RESULTS
  The clinical and radiographic evaluation at 3 months revealed total success rates of 100% in the FC and ABS groups. Success rates in FC and ABS groups at 6 months were 96.7% and 93.3% respectively. At the 12-month follow-ups, the total success rates in the FC, and ABS groups were 89.3% and 85.7%, respectively. When the groups were compared according to the time intervals, no significant differences were observed between the 3, 6, and 12 month values. The success rates of the materials decreased over time.
  
  
  CONCLUSIONS
  FC and ABS were found successful as pulp dressings in primary molars. ABS appears to be an alternative pulpotomy agent but periodical follow-ups must be considered to evaluate long term success rates.
authors.affiliation: Department of Paediatric Dentistry, Istanbul University, Istanbul, Turkey.
authors.forename: E
authors.initials: E
authors.lastname: Yaman
authors.forename: F
authors.initials: F
authors.lastname: Görken
authors.forename: A
authors.initials: A
authors.lastname: Pinar Erdem
authors.forename: E
authors.initials: E
authors.lastname: Sepet
authors.forename: Z
authors.initials: Z
authors.lastname: Aytepe
mesh_terms: D002648:Child; D003723:Dental Amalgam; D003731:Dental Caries / Q000628:therapy; D003789:Dental Pulp Exposure / Q000188:drug therapy; D003793:Dental Restoration, Permanent / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D005566:Formocresols / Q000627:therapeutic use*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008963:Molar / Q000000981:diagnostic imaging / Q000187:drug effects*; D010483:Periapical Diseases / Q000000981:diagnostic imaging; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000000981:diagnostic imaging; D057872:Pulp Capping and Pulpectomy Agents / Q000627:therapeutic use*; D011672:Pulpotomy / Q000379:methods*; D011859:Radiography; D012391:Root Resorption / Q000000981:diagnostic imaging; D016037:Single-Blind Method; D014094:Tooth, Deciduous / Q000000981:diagnostic imaging / Q000187:drug effects*; D016896:Treatment Outcome; D015035:Zinc Oxide-Eugenol Cement / Q000627:therapeutic use
chemical_list: D005566:Formocresols; D006490:Hemostatics; D010936:Plant Extracts; D057872:Pulp Capping and Pulpectomy Agents; D015035:Zinc Oxide-Eugenol Cement; C539751:ankaferd blood stopper; C031025:formocresol; D003723:Dental Amalgam